The stability and dissolution properties of solid glucagon/γ-cyclodextrin powder

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 412-420

  Matilainen, Laura ^a   Maunu, Sirkka Liisa ^b   Pajander, Jari ^a   Auriola, Seppo ^a   Jääskeläinen, Ilpo ^a   Larsen, Kim Lambertsen ^c   Järvinen, Tomi ^a   Jarho, Pekka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Cyclodextrins; Dissolution; Glucagon; Peptide; Solid state stability

Indexed keywords

GAMMA CYCLODEXTRIN; GLUCAGON; LACTOSE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPLEX FORMATION; DRUG SOLUBILITY; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; INFRARED SPECTROSCOPY; OXIDATION; PH; POWDER; PRIORITY JOURNAL; SOLID STATE; TEMPERATURE DEPENDENCE; TURBIDITY; ULTRAVIOLET RADIATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GAMMA-CYCLODEXTRINS; GLUCAGON; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 59349089190     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.11.006     Document Type: Article

References (36)

1. Banga A.K. Therapeutic Peptides and Proteins. Formulation, Processing and Delivery Systems (1995), Technomic Publishing Company, Inc, Lancacster, Pennsylvania
2. Beaven G.H., Gratzer W.B., and Davies H.G. Formation and structure of gels and fibrils from glucagon. Eur. J. Biochem. 11 (1969) 37-42
3. Becker G.W., Tackitt P.M., Bromer W.W., Lefeber D.S., and Riggin R.M. Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone. Biotechnol. Appl. Biochem. 10 (1988) 326-337
4. Brewster M.E., Hora M.S., Simpkins J.W., and Bodor N. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8 (1991) 792-795
5. Carpenter J.F., and Crowe J.H. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry. 28 (1989) 3916-3922
6. Carpenter J.F., Pikal M.J., Chang B.S., and Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14 (1997) 969-975
7. Carrasquillo K.G., Sanchez C., and Griebenow K. Relationship between conformational stability and lyophilization-induced structural changes in chymotrypsin. Biotechnol. Appl. Biochem. 31 Pt 1 (2000) 41-53
8. Chan H.K., Clark A.R., Feeley J.C., Kuo M.C., Lehrman S.R., Pikal-Cleland K., Miller D.P., Vehring R., and Lechuga-Ballesteros D. Physical stability of salmon calcitonin spray-dried powders for inhalation. J. Pharm. Sci. 93 (2004) 792-804
9. Coolican S.A., Jones B.N., England R.D., Flanders K.C., Condit J.D., and Gurd R.S. [25-oxindolylalanine]glucagon and [27-methionine sulfoxide]glucagon: preparation, purification, and characterization. Biochemistry 21 (1982) 4974-4981
10. Costantino H.R., Langer R., and Klibanov A.M. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sci. 83 (1994) 1662-1669
11. Fransson J., Florin-Robertsson E., Axelsson K., and Nyhlen C. Oxidation of human insulin-like growth factor I in formulation studies: kinetics of methionine oxidation in aqueous solution and in solid state. Pharm. Res. 13 (1996) 1252-1257
12. Frömming K.-H., and Szejtli J. Cyclodextrins in Pharmacy (1994), Kluwer Academic Publishers, Dordrecht, The Netherlands
13. Griebenow K., Laureano Y.D., Santos A.M., Montanez Clemente I., Rodriguez L., Vidal M.W., and Barletta G. Improved enzyme activity and enantioselectivity in organic solvents by methyl-β-cyclodextrin. J. Am. Chem. Soc. 121 (1999) 8157-8163
14. Hageman M.J. The role of moisture in protein stability. Drug Dev. Ind. Pharm. 14 (1988) 2047-2070
15. Hermeling S., Crommelin D.J., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 (2004) 897-903
16. Hora M.S., Rana R.K., and Smith F.W. Lyophilized formulations of recombinant tumor necrosis factor. Pharm. Res. 9 (1992) 33-36
17. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 (1997) 147-162
18. Irie T., and Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36 (1999) 101-123
19. Iwai J., Ogawa N., Nagase H., Endo T., Loftsson T., and Ueda H. Effects of various cyclodextrins on the stability of freeze-dried lactate dehydrogenase. J. Pharm. Sci. 96 (2007) 3140-3143
20. Joshi A.B., Rus E., and Kirsch L.E. The degradation pathways of glucagon in acidic solutions. Int. J. Pharm. 203 (2000) 115-125
21. Katakam M., and Banga A.K. Aggregation of proteins and its prevention by carbohydrate excipients: albumins and gamma-globulin. J. Pharm. Pharmacol. 47 (1995) 103-107
22. Katakam M., and Banga A.K. Aggregation of insulin and its prevention by carbohydrate excipients. PDA J. Pharm. Sci. Technol. 49 (1995) 160-165
23. Lai M.C., and Topp E.M. Solid-state chemical stability of proteins and peptides. J. Pharm. Sci. 88 (1999) 489-500
24. Li S., Patapoff T.W., Overcashier D., Hsu C., Nguyen T.H., and Borchardt R.T. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J. Pharm. Sci. 85 (1996) 873-877
25. Matilainen L., Larsen K.L., Wimmer R., Keski-Rahkonen P., Auriola S., Järvinen T., and Jarho P. The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/γ-CD inclusion complexes. J. Pharm. Sci. 97 (2008) 2720-2729
26. Nooijen W.J., and Kempen H.J. Immunogenicity and bioactivity of glucagon, modified at methionine-27. Horm. Metab. Res. 11 (1979) 459-463
27. Onoue S., Ohshima K., Debari K., Koh K., Shioda S., Iwasa S., Kashimoto K., and Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res. 21 (2004) 1274-1283
28. Onoue S., Iwasa S., Kojima T., Katoh F., Debari K., Koh K., Matsuda Y., and Yajima T. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J. Chromatogr. A 1109 (2006) 167-173
29. Prestrelski S.J., Tedeschi N., Arakawa T., and Carpenter J.F. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys. J. 65 (1993) 661-671
30. Roy I., and Gupta M.N. Freeze-drying of proteins: some emerging concerns. Biotechnol. Appl. Biochem. 39 (2004) 165-177
31. Sonne O., Larsen U.D., and Markussen J. The effect of oxidation of the Met27 residue of [125I]monoiodoglucagon on receptor-binding affinity. Hoppe Seylers Z. Physiol. Chem. 363 (1982) 95-101
32. Stigsnaes P., Frokjaer S., Bjerregaard S., van de Weert M., Kingshott P., and Moeller E.H. Characterisation and physical stability of PEGylated glucagon. Int. J. Pharm. 330 (2007) 89-98
33. Sun L., and Gardella Jr. J.A. The solid state oxidation of methionine containing peptide: a preliminary study using time of flight secondary ion mass spectrometry. Pharm. Res. 17 (2000) 859-862
34. The Merck Index. 1996. Merck&Co Inc., New Jersey, U.S.A.
35. USP27. 2003. United States Pharmacopeial Convention, Rockville, MD, USA.
36. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289 (2005) 1-30